Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
131. |
ECCT/22/03/09 | GBT 132-Inclacumub PH3 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises. |
Principal Investigator(s) 1. Videlis N Nduba 2. Bernhards Ragama Ogutu 3. Fredrick Asirwa Chite Site(s) in Kenya 1. KEMRI Siaya Clinical Research Annex (Siaya county) 2. KEMRI/CRDR (Nairobi City county) 3. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county) 4. Strathmore University Medical Centre (Nairobi City county) |
30-05-2022 |
View |
132. |
ECCT/22/03/02 | MOVe AHEAD STUDY A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19 |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya KEMRI RCTP KISUMU |
31-05-2022 |
View |
133. |
ECCT/22/03/01 | The \"NOVATION-1\" Trial A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19 |
Principal Investigator(s) 1. Dr John Kinuthia Site(s) in Kenya 1. Center for Research in Therapeutic Sciences(CREATES) (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 3. KEMRI Kericho (Kericho county) 4. KEMRI Siaya (Kisumu county) 5. Kenyatta National Hospital (Nairobi City county) |
27-05-2022 |
View |
134. |
ECCT/22/02/01 | An Open label Inclacumab study An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Fredrick Asirwa Chite 3. Videlis N nduba 4. Prof Jessie N Githanga Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital. (Nairobi City county) 6. Strathmore University Medical Centre (Nairobi City county) |
16-05-2022 |
View |
135. |
ECCT/22/01/06 | AIKILI Technology Feasibility and accuracy of nanosensor-based breast cancer diagnosis at the point-of-care-AIKILI technology |
Principal Investigator(s) 1. Laura Kelley Kelley Site(s) in Kenya Aga Khan University Hospital, Nairobi. |
21-03-2022 |
View |
136. |
ECCT/22/01/05 | STEP-Mag Trial Simplified Treatment for Eclampsia Prevention using Magnesium sulfate: A phase III, randomized, open label, active controlled, multicountry, multicentre, non-inferiority trial of simplified magnesium sulfate regimen for eclampsia prophylaxis (The STEP-Mag Trial) |
Principal Investigator(s) 1. Zahida Qureshi Site(s) in Kenya 1. Wamalwa Kijana TRH (Trans Nzoia county) 2. Mama Lucy Kibaki Hospital (Nairobi City county) 3. Mbagathi County referral Hospital (Nairobi City county) |
15-05-2022 |
View |
137. |
ECCT/22/01/04 | SKYSCRAPER 07 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Mansoor Saleh Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
22-05-2022 |
View |
138. |
ECCT/22/01/03 | lidERA A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer |
Principal Investigator(s) 1. Mansoor Saleh Site(s) in Kenya 1. International Cancer Institute (ICI) (Uasin Gishu county) 2. Aga Khan University Hospital (Nairobi City county) |
08-05-2022 |
View |
139. |
ECCT/22/01/01 | ASTEFANIA A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY |
Principal Investigator(s) 1. Mansoor Saleh 2. Fredrick Chite Asirwa Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
21-07-2022 |
View |
140. |
ECCT/21/12/07 | GBT 132- Inclacumab Phase 3 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises. |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Videlis N Nduba 3. Fredrick Asirwa Chite Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) |
21-03-2022 |
View |